Corcept Therapeutics Inc. (CORT) — 分析摘要
Corcept Therapeutics Inc.（CORT）的市值为9.22十亿美元，最近一年的营收同比增长了+12.8%。净利润率为13.1%。当前市盈率为194.8倍。
核心要点
- 营收同比变化+12.8%
- 净利润率13.1%
- 市盈率194.8倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，CORT的营收增长为+12.8%，市盈率为194.8倍。
Corcept Therapeutics Inc. (CORT)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
净利润较上一期下降 52.5%。
毛利率为 98.3% — 请核实：除纯软件/IP外极少有企业维持 >90% 毛利率
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
730
总部
REDWOOD CITY, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。